Orally Disintegrating Antipsychotics May Promote Compliance and Adherence in Patients With Schizophrenia

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Kane et al., in their recent (January 2005) CME activity “Optimizing Pharmacotherapy to Maximize Outcome in Schizophrenia,”1 recommend using a long-acting depot injection in patients who fail to adhere to antipsychotic treatment. While depot medications ensure compliance, they may not foster certain aspects of the doctor-patient relationship, and even with depot medication, about 25% of patients stop keeping scheduled appointments and no longer receive depot injections within 1 year after starting treatment.2 Furthermore, depot medications may be associated with an increased risk for prolonged side effects.3

J Clin Psychiatry 2005;66(11):1493-1494